Cargando…
Clinical Evaluation of FOXO1 as a Tumor Suppressor in Prostate Cancer
OBJECTIVE: Prostate cancer (PCa) is considered the most serious cancer in the world. Nevertheless, the accuracy of current biomarkers, such as pathological staging, Gleason's score, and serum prostate-specific antigen (PSA) levels, is limited. FOXO1 is a key downstream effector of PTEN and a tu...
Autores principales: | Yang, Ning, Wu, Jiawen, Zhang, Tiancheng, Yang, Fan, Shao, Jinyan, He, Chang, Qin, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452405/ https://www.ncbi.nlm.nih.gov/pubmed/34552661 http://dx.doi.org/10.1155/2021/8773423 |
Ejemplares similares
-
FOXO3 is a latent tumor suppressor for FOXO3-positive and cytoplasmic-type gastric cancer cells
por: Tsuji, Toshikatsu, et al.
Publicado: (2021) -
Tumor Suppressor Role and Clinical Significance of the FEV Gene in Prostate Cancer
por: Liang, Yu-Xiang, et al.
Publicado: (2022) -
TWIST2: A new candidate tumor suppressor in prostate cancer
por: Zhao, Chengxiao, et al.
Publicado: (2019) -
Exosomal LINC01213 Plays a Role in the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manners
por: Guo, Zhuifeng, et al.
Publicado: (2022) -
Regulation of the Tumor Suppressor FOXO3 by the Thromboxane-A(2) Receptors in Urothelial Cancer
por: Sobolesky, Philip M., et al.
Publicado: (2014)